Atrial Fibrillation During an Exploration Class Mission. Mark Lipsett MD, PhD Douglas Hamilton MD, PhD Jay Lemery MD James Polk DO



Similar documents
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Atrial Fibrillation Management Across the Spectrum of Illness

Recurrent AF: Choosing the Right Medication.

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Atrial Fibrillation The Basics

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose

Unrestricted grant Boehringer Ingelheim

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Atrial Fibrillation An update on diagnosis and management

Atrial fibrillation. Quick reference guide. Issue date: June The management of atrial fibrillation

Episode 20 Atrial fibrillation Prepared by Dr. Lucas Chartier

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

HTEC 91. Topic for Today: Atrial Rhythms. NSR with PAC. Nonconducted PAC. Nonconducted PAC. Premature Atrial Contractions (PACs)

Presenter Disclosure Information

2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?

Atrial Fibrillation (AF) Explained

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Quiz 4 Arrhythmias summary statistics and question answers

PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia

Anticoagulation For Atrial Fibrillation

Managing the Patient with Atrial Fibrillation

Atrial fibrillation (AF) care pathways. for the primary care physicians

An Introduction to Tachyarrhythmias R. A. Seyon MN, NP, CCN(C) & Dr. R. G. Williams

Anticoagulation before and after cardioversion; which and for how long

Anticoagulation Therapy Update

Management of Atrial Fibrillation in Heart Failure

Equine Cardiovascular Disease

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy

Atrial Fibrillation (AF) March, 2013

510(k) Summary May 7, 2012

Nursing Care and Considerations for Patients with Atrial Fibrillation. Kris Kinghorn RN, MSN, ANP-BC

Ngaire has Palpitations

ATRIAL FIBRILLATION IN THE 21 ST CENTURY TIMOTHY DOWLING, D.O. FAMILY PHYSICIAN

TABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

Atrial & Junctional Dysrhythmias

Atrial Fibrillation. Information for you, and your family, whänau and friends. Published by the New Zealand Guidelines Group

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Protocol for the management of atrial fibrillation in primary care

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy

Anticoagulants in Atrial Fibrillation

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

What Are Arrhythmias?

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Surgeons Role in Atrial Fibrillation

National Medicines Information Centre

Classification (ACC/AHA/ESC 2006)

Visited 9/14/2011. What is Atrial Fibrillation? What you need to know about Atrial Fibrillation. The Normal Heart Rhythm. 1 of 7 9/14/ :50 AM

Dorset Cardiac Centre

What to Know About. Atrial Fibrillation

Introduction 2/9/2015

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

Sign up to receive ATOTW weekly - wfsahq@anaesthesiologists.org

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

A 35 yo female presents increasing fatigue and shortness of breath for several days. She is found to be in atrial fibrillation.

ACLS PHARMACOLOGY 2011 Guidelines

Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter

Atrial Fibrillation: Rate Control Strategies

Difficult Cases in Atrial Fibrillation. Ascot Cardiology GP Symposium April 2014

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Atrial Fibrillation and Ablation Therapy: A Patient s Guide

Treatments to Restore Normal Rhythm

Management of Atrial Fibrillation in the Emergency Department

Tachyarrhythmias (fast heart rhythms)

5 MILLION AMERICANS 1. Atrial Fibrillation (AFib) AFib affects an estimated

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015

Traditionally, the goal of atrial fibrillation (AF)

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

The P Wave: Indicator of Atrial Enlargement

A Patient Guide to Atrial Fibrillation and Catheter Ablation

How do you decide on rate versus rhythm control?

Clinical Guideline for the Management of Pot Operative Atrial Fibrillation

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Atrial fibrillation/flutter: When to refer, What tests, What meds

ACUTE ATRIAL FIBRILLATION TREATMENT IN THE SURGICAL PATIENT

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014

8 Peri-arrest arrhythmias

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?

NORTHERN NETWORK OF CARDIAC CARE GUIDELINES FOR THE DETECTION AND MANAGEMENT OF ATRIAL FIBRILLATION (AF)

These guidelines have been withdrawn

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI

Atrial Fibrillation The High Risk Obese Patient

RUSSELLS HALL HOSPITAL EMERGENCY DEPARTMENT

Atrial Fibrillation - management AF in primary care

Chronic Atrial Fibrillation in the Elderly

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

TOP 5. The term cardiac arrhythmia encompasses all cardiac. Arrhythmias in Dogs & Cats. Sinus Arrhythmia. TOP 5 Arrhythmias Seen in Dogs & Cats

Primary-care physicians are frequently

Management of Symptomatic Atrial Fibrillation

STROKE PREVENTION IN ATRIAL FIBRILLATION

Atrial fibrillation (AF) is the most common sustained

9/5/14. Objectives. Atrial Fibrillation (AF)

Transcription:

Atrial Fibrillation During an Exploration Class Mission Mark Lipsett MD, PhD Douglas Hamilton MD, PhD Jay Lemery MD James Polk DO

Disclosure Information 82nd Annual Scientific and Human Performance Meeting Mark Lipsett, Douglas Hamilton, Jay Lemery, James Polk Have no financial relationships to disclose The authors will not discuss off-label use and/or investigational use in this presentation

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

1 Background Outline

Mission Background 1 * * * After a several month journey, the 7-member crew is preparing to enter a low Mars orbit You, the flight surgeon, have just received the mission commander s video message supplemented with the crew s biometrics & health status The message, delayed by the 20 min transmission lag, confirms the return to duty criteria for mission specialist (M.C.)

Medical Background 1 * M.C., a 51-yo mission scientist had presented 2 months earlier via a store & forward PMC with the chief complaint of Cardiac Palpitations * M.C. indicated feeling a strange fluttering & pressure in his chest during these bouts * Three episodes, lasting ~3hr & terminating with bed rest, were diagnosed as Paroxysmal Atrial Fibrillation (PAF)

Medical Background 1 * M.C. s cardiac exam 30 days before mission takeoff indicated: ø CAD risk factors ø cardiac Ca 2+ score ø significant ectopy during Holter

Medical Background 1 * M.C. s cardiac exam 30 days before mission takeoff indicated: ø CAD risk factors ø cardiac Ca 2+ score ø significant ectopy during Holter * EKG obtained during all three PAF episodes revealed AF with: ventricular rate of ~150 bpm narrow complex QRS ø ST- or T-wave abnormalities

Medical Background 1 * EKG obtained during all 3 PAF episodes revealed AFwith: ventricular rate of ~150 bpm narrow complex QRS ø ST- or T-wave abnormalities

Medical Background 1 * M.C. s cardiac exam 30 days before mission takeoff indicated: ø CAD risk factors ø cardiac Ca 2+ score ø significant ectopy during Holter * EKG obtained during all three PAF episodes revealed AF with: ventricular rate of ~150 bpm narrow complex QRS ø ST- or T-wave abnormalities * M.C. indicated having an URTI 3 weeks before the first bout of in which PAF pseudo-ephedrine was used and a slight hand tremor was noted

Medical Background 1 AF & the Astronaut Corps * Since 1950s, 17 cases of AF have been diagnosed amongst 317 active & retired astronauts (~5%)

Medical Background 1 AF & the Astronaut Corps * Since 1950s, 17 cases of AF have been diagnosed amongst 317 active & retired astronauts (~5%) * Since 2001, 5 astronauts underwent RFA treatment for atrial arrhythmias

Medical Background 1 AF & the Astronaut Corps * Since 1950 s 17 cases of AF have been diagnosed amongst 317 active & retired astronauts (~5%) * Since the 2001, 5 astronauts underwent RFA treatment for atrial arrhythmias * Of significance is the younger age (~40s) in which these arrhythmias are detected (vs >60 years)

Medical Background 1 AF & the Astronaut Corps * Since 1950s, 17 cases of AF have been diagnosed amongst 317 active & retired astronauts (~5%) * Since 2001, 5 astronauts underwent RFA treatment for atrial arrhythmias * Of significance is the younger age (~40s) in which these arrhythmias are detected (vs >60 years) * Due to: better health surveillance? higher vagal tone? random chance? gravitational-flux induced?

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

Outline 2 Causes of Atrial Fibrillation

Terrestrial Mechanisms 2 of Atrial Fibrillation * Structural Heart Disease Pericarditis * * Metabolic Disturbances * Ectopic Beats Myocardial Stretch * * Idiopathic

Mission Question 1: 2 What Caused M.C. s AF? a CO poisoning f Pericarditis b Cardiomyopathy g Post-viral thyrotoxicosis c Iatrogenic h Pulmonary embolism d Idiopathic AF (lone AF) i Structural e Myocardial infarction

Mission Question 1: 2 What Caused M.C. s AF? d Idiopathic AF (lone AF)

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

3 Mission to Mars Outline

Continuation of Mission 3 * The space vehicle is preparing to fire it s engines to enter a parking orbit around Mars * Any chance of returning to Earth in less than 1 year is impossible

Mission Question 2: 3 At this point you decide to... a b c d continue mission, watchful waiting, EKG when symptomatic Abort mission due to poor prognosis & risk of thromboembolic event continue mission, start ASA daily with bi-monthly EKG follow-up exams continue mission, start a β-blocker for possible thyrotoxic disease

Mission Question 2: 3 At this point you decide to... c continue mission, start ASA daily with bi-monthly EKG follow-up exams

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

Outline 4 Medical Resources

The Mission at Home 4 * The last few weeks have been a harrowing experience for you as the mission Flight Surgeon

The Mission at Home 4 * The last few weeks have been a harrowing experience for you as the mission flight surgeon * You have organized an international aerospace cardiology expert panel to decide:

The Mission at Home 4 * The last few weeks have been a harrowing experience for you as the mission Flight Surgeon * You have organized an international aerospace cardiology expert panel to decide: abort mission, sling-shot burn around Mars and return to Earth within 6 months

The Mission at Home 4 * The last few weeks have been a harrowing experience for you as the mission Flight Surgeon * You have organized an international aerospace cardiology expert panel to decide: abort mission, sling-shot burn around Mars and return to Earth within 6 months continuing with the Mars landing and subsequent 1-year surface endeavour

The Mission at Home 4 Crew Supplies * Adequate ASA for the whole mission

The Mission at Home 4 Crew Supplies * Adequate ASA for the whole mission * Insufficient anti-coagulation, rate control & rhythm control medications for one astronaut

The Mission at Home 4 Crew Supplies * Adequate ASA for the whole mission * Insufficient anti-coagulation, rate-control & rhythm control medications for one astronaut * An Automatic External Defibrillator (AED) device

Mission Question 3: 4 Inquest In your testimony to the international experts conference, you state that: a b c d ASA is just as effective as warfarin for anticoagulation the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction low-molecular weight heparin is not effective in treating thromboembolic risks associated with AF Immediate electrical cardioversion would preclude the need for anticoagulation

The Mission at Home 4 Inquest * At the experts panel, you present an extensive premission risk/benefit study analysis: long-duration mission profile age and excellent health of crew risk of lone AF and subsequent crew member impact, including fatal stroke * Conclusions: impact & risk of warfarin therapy > ASA therapy * At time of mission planning, newer direct thrombin inhibitors not yet vetted

Mission Question 3: 4 Inquest In your testimony to the international experts conference, you state that: a b c d ASA is just as effective as warfarin for anticoagulation the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction low-molecular weight heparin is not effective in treating thromboembolic risks associated with AF Immediate electrical cardioversion would preclude the need for anticoagulation

Mission Question 3: 4 Inquest In your testimony to the international experts conference, you state that: b the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

Outline Distant Medical Management

Continuation of Mission 5 * Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return

Continuation of Mission 5 * Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return * Holter confirmed: AF - rapid ventricular response 165 bpm pressure 90/50 mmhg

Continuation of Mission 5 * Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return * Holter confirmed: AF - rapid ventricular response 165 bpm pressure 90/50 mmhg * M.C. notes feeling uncomfortable, but denies chest pressure or dyspnea

Mission Question 4: 5 At this point, you would recommend: a b c d Nothing, M.C. can be expected to spontaneously convert to NSR in the next 24 hours Rate control and reassess Rate control and initiate immediate chemical cardioversion Immediate electrical cardioversion due to hypotension

Mission Question 4: 5 At this point, you would recommend: b Rate control and reassess

Mission Question 4: 5 * Rate control first choice, AF can ventricular filling by ~20%

Mission Question 4: 5 * Rate control first choice, AF can ventricular filling by ~20% * Ca 2+ channel blocker vs β-blocker, side-effects

Mission Question 4: 5 * Rate control first choice, AF can ventricular filling by ~20% * Ca 2+ channel blocker vs β-blocker, side-effects * Spontaneous conversion common <24 hours (~67% )

Mission Question 4: 5 * Rate control first choice, AF can ventricular filling by ~20% * Ca 2+ channel blocker vs β-blocker, side-effects * Spontaneous conversion common <24 hours (~67% ) * Electrical cardioversion only when symptomatic

Outline 1 Background 2 Causes of Atrial Fibrillation 3 Mission to Mars 4 Medical Resources 5 Distant Medical Management 6 Mission Summary

Outline 6 Mission Summary

Continuation of Mission 6 * Crew member M.C. continued to take ASA and was acutely rate controlled with Ca 2+ CB

Continuation of Mission 6 * Crew member M.C. continued to take ASA and was acutely rate controlled with Ca 2+ CB * Of interest was his conversion back to NSR during the 4 minutes of 3Gx loading during lift off from the Martian surface

Continuation of Mission 6 * Crew member M.C. continued to take ASA and was acutely rate controlled with Ca 2+ CB * Of interest was his conversion back to NSR during the 4 minutes of 3Gx loading during lift off from the Martian surface * M.C. remained in NSR for the duration of the journey back to Earth and the mission was completed successfully

Summary * This case was to acquaint the audience with the tremendous challenges that face the flight surgeon and medical team when supporting a space mission

Summary * This case was to acquaint the audience with the tremendous challenges that face the FS and medical team when supporting a space mission * Limited crew training time, medical hardware & pharmaceuticals manifested dictate aggressive 1 & 2 prevention strategies to protect a multibillion dollar asset like the ISS or a mission to the Moon or Mars

Acknowledgements Dept. Anaesthesia Memorial University Wyle Life Sciences NASA - JSC CSA Jillian Pashley